VivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCs
Rhea-AI Summary
VivoSim (Nasdaq: VIVS) reported that its NAMkind™ liver and intestine models have been validated for predicting antibody drug conjugate (ADC) toxicity, showing close correlation with clinical safety outcomes for approved ADCs on March 24, 2026.
Tests distinguished payload vs antibody vs linker toxicity (examples: gemtuzumab ozogamicin, enfortumab vedotin, trastuzumab emtansine, trastuzumab deruxtecan). NAMkind™ services are available in the US, Europe, Korea, and China, and VivoSim is scaling capacity to meet global demand.
Positive
- NAMkind models validated for ADC liver and intestine toxicity prediction
- Correlation to clinical outcomes demonstrated with approved ADCs
- Differentiates payload, antibody, and linker toxicity signatures
- Global service availability across US, Europe, Korea, and China
Negative
- No numeric performance metrics (sensitivity/specificity) were disclosed in the announcement
- Scaling needs noted—company says it is continuing to scale capacity without quantified timelines
News Market Reaction – VIVS
In the Mar 24 session, VIVS declined 2.41%, reflecting a moderate negative market reaction. Argus tracked a peak move of +6.8% during that session. Argus tracked a trough of -18.1% from its starting point during tracking. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility. Trading volume was very high at 3.2x the daily average, suggesting heavy selling pressure.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 03 | Sales leadership hire | Positive | -12.7% | Appointed Vice President of Global Sales to drive commercial expansion. |
| Feb 11 | ADC data preview | Positive | +0.0% | Announced upcoming presentation of ADC validation data at SOT meeting. |
| Jan 29 | APAC distributor deal | Positive | +71.8% | Named new distributors in Korea and China for NAMKind toxicology services. |
| Jan 06 | New CSO appointment | Positive | +4.6% | Appointed Amar Sethi as Chief Scientific Officer to lead scientific strategy. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent VivoSim news has mostly seen price moves align with positive corporate developments, though the March 3 sales leadership hire drew a negative reaction despite constructive strategic framing.
Over the last several months, VivoSim has focused on strengthening its NAMkind™ platform and commercial reach. On Jan 6, 2026, it appointed a new Chief Scientific Officer, followed by expanded Asia-Pacific distribution on Jan 29, which saw a 71.76% move. The company later previewed ADC data on Feb 11 and added a Vice President of Global Sales on Mar 3, though that hire coincided with a 12.73% decline. Today’s ADC validation update builds directly on the February data preview and broader commercial expansion efforts.
Key Terms
antibody drug conjugates medical
cytotoxic payloads medical
linker cleavage medical
target engagement medical
epithelium medical
permeability medical
new approach methodologies medical
toxicology medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
ADCs are a major new market; Company demonstrates ability to discern antibody toxicity from payload toxicity and show differential linker chemistry toxicity
SAN DIEGO, March 24, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety, today announced at the Society of Toxicology (“SOT”) meeting in San Diego, CA, that its NAMkind™ liver and NAMkind™ Intestine models have been validated for predicting toxicity and side effect profiles of antibody drug conjugates (ADCs).
When considering the hundreds of ADCs in development across the globe, the potential for off-target toxicity due to their common use in oncology to deliver cytotoxic payloads, and a lack of current available scientific solutions to separate anticancer activity from unwanted cytotoxicity, the Company believes that the use of NAMkind™ models becomes a powerful tool to use in conjunction with existing methods to select and improve the best ADC candidates for drug development.
Testing of approved ADC therapies in NAMkind™ models shows close correlation with clinical results
VivoSim NAMkind™ liver model was shown to clearly see the toxicity of liver toxic ADCs such as gemtuzumab ozogomicin and clearly showed drugs with low liver toxicity such as enfortumab vedotin as lacking liver toxicity. Issues of linker cleavage and target engagement can be studied, as differential toxicity between drugs like trastuzumab emtansine and trastuzumab deruxtecan were demonstrated with strong comparability to clinical outcomes.
NAMkind™ intestine models were also validated with ADCs and have the ability to detect differential effects such as antibody activity on epithelium, payload impact on epithelium, and overall ADC impact on epithelium. Permeability endpoints are sensitive to the exact chemical compound, be it ADC, antibody alone, or payload.
“These ADC toxicity results show a close correlation to clinical safety outcomes,” said Amar Sethi, Chief Scientific Officer at VivoSim. “We consider these models validated for ADC use and think that our partners may be able to screen out toxicities during lead candidate optimization or earlier stages, which may result in greater success in the clinic at eliminating cancers using drugs with limited side effect profiles,” he continued.
“With clearly demonstrated success in detecting differential toxicity in ADCs, our NAMkind models are now well-established at the cutting edge of the field,” said Keith Murphy, VivoSim’s Executive Chairman. “We continue to trailblaze into new modalities and empower our partners in new ways.”
NAMKind™ liver and small intestine toxicology services are now available in the US, Europe, and via local distributor engagement across Korea and China, with VivoSim continuing to scale capacity to support expanding global demand and urgent, real-world development needs.
About VivoSim Labs
VivoSim Labs, Inc. (“VivoSim” and the “Company”), is a pharmaceutical and biotechnology services company that is focused on providing testing of drugs and drug candidates in three-dimensional (“3D”) human tissue models of liver and intestine. The Company offers partners liver and intestinal toxicology insights using its new approach methodologies (“NAM”) models. The Company anticipates accelerated adoption of human tissue models following the U.S. Food and Drug Administration (“FDA”) announcement on April 10, 2025 to refine animal testing requirements in favor of these non-animal NAM methods. VivoSim Labs operates from San Diego, CA. Visit www.vivosim.ai.
Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Forward-looking statements include statements regarding NAMKind™, including the use of NAMkind™ models in conjunction with existing methods to select and improve the best ADC candidates for drug development and the Company’s models being well-established at the cutting edge of the field; VivoSim’s partners’ ability to screen out toxicities during lead candidate optimization or earlier stages, which may result in greater success in the clinic at eliminating cancers using drugs with limited side effect profiles; VivoSim’s ability to trailblaze into new modalities and empower their partners in new ways; and the Company’s scaling capacity to support expanding global demand and development needs. Such forward-looking statements are not guarantees of performance and actual actions or events could differ materially from those contained in such statements. These risks and uncertainties and other factors are identified and described in more detail in the Company’s filings with the SEC, including its Annual Report on Form 10-K filed with the SEC on June 5, 2025, as such risk factors are updated in its most recently filed Quarterly Report on Form 10-Q filed with the SEC on February 11, 2026. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that the Company may issue in the future. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events, or circumstances or to reflect the occurrence of unanticipated events.
Contact(s):
Investor Relations
info@vivosim.ai
VivoSim Labs, Inc.
